Lithium for bipolar disorder has more evidence behind it than almost any other mood-stabilizing medication — decades of trials, real-world outcomes, and guideline endorsements that few psychiatric drugs can match. And yet it’s one of the most frequently avoided, discontinued, or never-tried treatments for people who might genuinely benefit from it. If you’ve heard mixed things about lithium, or if a clinician once mentioned it and you filed it away as “too complicated,” that’s an understandable place to be. This article is a clear-eyed look at what the research actually says — the benefits, the real risks, the monitoring, and who tends to respond best.
If you’re wondering whether lithium is right for your situation, a conversation with a bipolar-specialized clinician is a good place to start — no commitment required. See a bipolar specialist online
At a Glance
- Lithium has been used to treat bipolar disorder since 1949 and received FDA approval in 1970 — making it one of the longest-studied psychiatric medications, with over 75 years of evidence behind it.
- A Cochrane review found relapse rates of 36% on lithium versus 61% on placebo — a meaningful difference that has held up across decades of research.
- About one-third of people who take lithium are excellent responders, experiencing complete or near-complete prevention of mood episodes.
- Lithium requires regular blood monitoring for kidney and thyroid function — this isn’t a reason to avoid it, but it does require an engaged prescribing relationship.
- Side effects are common but many are manageable; knowing what to expect makes them easier to navigate with your prescriber.
What Is Lithium for Bipolar Disorder?
Lithium is a naturally occurring element — a metal in the same family as sodium and potassium — that has been used as a psychiatric medication for over 75 years. As a mood stabilizer (a class of medications that reduces the frequency and severity of both manic and depressive episodes), it remains one of the most prescribed and most studied treatments for bipolar disorder.
According to the FDA, lithium is a mood-stabilizing agent first approved in the United States on April 6, 1970. It is sold under the brand names Eskalith and Lithobid, and also available as generic lithium carbonate and lithium citrate. The FDA drug label confirms that lithium is indicated both for the treatment of acute manic episodes and as a maintenance treatment for individuals with bipolar disorder.
NAMI notes that lithium (Lithobid, Eskalith) is effective at stabilizing mood and preventing the extreme highs and lows of bipolar disorder, though periodic blood tests are required because lithium can affect thyroid and kidney function over time. That monitoring requirement is a real consideration — and one this article addresses directly.
The History of Lithium: From Mineral Springs to the Gold Standard
The story of lithium in psychiatry is genuinely remarkable — and understanding it helps explain why the medication carries so much weight in clinical guidelines today.
In the 19th century, lithium-rich mineral spring waters were believed to have healing properties, used with varying degrees of rigor for conditions ranging from gout to “brain exhaustion.” These early uses were largely anecdotal. What changed everything was a single, careful observation made in 1949.
Australian psychiatrist John Cade reported successfully using lithium citrate to treat patients with mania in 1949, publishing findings that would eventually transform psychiatric care. Cade had been studying guinea pigs and noticed that lithium appeared to produce sedation; he then cautiously tested it in ten patients with mania. The results were striking.
The findings were confirmed in a randomized controlled trial led by Danish psychiatrist Mogens Schou in 1954, establishing the scientific foundation that Cade’s observations had suggested. Schou spent decades championing lithium’s use in bipolar disorder — at times against resistance from a psychiatric establishment skeptical of a mineral as a psychiatric treatment. The FDA approved lithium for acute mania in 1970 and for maintenance therapy in 1974 — milestones that opened access to the medication for patients across the United States.
Research has since estimated that the savings brought by lithium between 1970 and 1991 alone were approximately $8 billion per year in the United States, reflecting how dramatically it reduced hospitalizations and disability. That figure is a proxy for something more personal: for the many people who found stability on lithium during those decades, it changed the arc of their lives.
Key Takeaway: Lithium’s track record spans over 75 years of clinical use — an unusually long evidence base that most newer medications cannot match.
How Lithium Works
One of the honest complications with lithium is that researchers still don’t have a single, complete explanation of why it works. What is understood, though, is increasingly detailed — and points to mechanisms that go well beyond straightforward neurotransmitter adjustment.
GSK-3β Inhibition
One of lithium’s most studied mechanisms involves an enzyme called GSK-3β — glycogen synthase kinase-3 beta, an enzyme involved in cell signaling, inflammation regulation, and neuroprotection — that appears central to its effects on the brain. Research has established that lithium is a selective inhibitor of GSK-3β, and that this action may contribute significantly to its neuroprotective function. When GSK-3β is overactive, it can promote cell death and inflammation in the brain; by inhibiting it, lithium appears to create conditions more favorable to neuronal survival and stability.
This isn’t a metaphor — studies have found that lithium inhibits GSK-3β and that this mechanism contributes to neuroprotective effects that may explain some of its unique clinical properties, including effects that go beyond conventional mood stabilization.
BDNF Upregulation and Brain Volume
Lithium also appears to increase levels of BDNF — brain-derived neurotrophic factor, a protein that supports the growth, maintenance, and survival of neurons. BDNF is often described as the brain’s “fertilizer”: it promotes neuroplasticity (the brain’s ability to form and reorganize connections) and is associated with resilience against stress and mood dysregulation.
Research has found increased bilateral hippocampal volume after 2–4 years of lithium treatment in previously drug-naïve individuals with bipolar disorder. The hippocampus — a brain region central to memory, stress response, and emotional regulation — is often smaller in people with untreated bipolar disorder. The same research found that only lithium-responders showed increases in gray matter in prefrontal areas, suggesting these structural changes may be linked to the medication’s therapeutic effects rather than being incidental.
This body of evidence has led many researchers to describe lithium not simply as a symptom-management tool, but as a potentially disease-modifying agent — a distinction we’ll return to shortly.
What the Evidence Actually Says
If you want to understand where lithium stands in the evidence landscape for bipolar disorder, the data is genuinely impressive — though it also comes with important nuance about who responds and to what degree.
Relapse Prevention: The Cochrane Data
A comprehensive review of lithium’s use across the lifespan found that a Cochrane meta-analysis reported a relapse risk of 36% for patients on lithium versus 61% for those on placebo — with a number needed to treat (NNT) of 4. An NNT of 4 means that for every four people treated with lithium instead of placebo, one additional person avoids a relapse. In psychiatry, that’s a strong signal.
Long-term data shows that approximately 30% of patients on lithium experienced recurrences, compared to 70% on placebo, with around 35% of patients not experiencing any episodes on lithium monotherapy over a ten-year period.
Response Rates: The One-Third Framework
The research consistently points to a roughly tripartite distribution of responses. According to NIMH-funded research involving a landmark genome-wide study across 2,563 patients with bipolar disorder: for some patients, lithium is very effective, virtually eliminating symptoms; about a third respond incompletely; and another third don’t respond at all.
Longer-term studies confirm that about one-third of lithium-treated patients are excellent responders who show total prevention of episodes, roughly one-third are partial responders with reduced frequency or severity, and the remaining third do not respond meaningfully to lithium monotherapy. Understanding this distribution matters — not as a reason to dismiss lithium, but as context for having realistic conversations with your prescriber about what to watch for.
Guideline Recommendations
The Canadian Network for Mood and Anxiety Treatments (CANMAT) 2018 guidelines — one of the most widely cited guideline sets in bipolar care — list lithium and lamotrigine as first-line agents for bipolar I depression, and lithium alongside quetiapine and divalproex as first-line treatments for acute mania. Across the lifespan evidence base, lithium is recommended by all relevant treatment guidelines as a first-line treatment for maintenance.
A Potential Disease-Modifying Effect
Perhaps most significantly, a 2025 paper in The Lancet Psychiatry reviewed clinical trial and cohort study evidence and concluded that lithium is effective and probably superior to other medications, with long-term outcomes better in lithium-treated regimens than in non-lithium ones. The framing of lithium as “disease-modifying” — meaning it may alter the underlying course of the illness, not just mask symptoms — represents a shift in how researchers are thinking about its role.
Research has also noted that lithium is the only drug with demonstrated prophylactic (preventive) efficacy across all three major domains: manic symptoms, depressive symptoms, and suicidal symptoms — a breadth no other mood stabilizer has replicated.
If you’re navigating medication decisions more broadly, the medication guide for bipolar depression provides a fuller picture of the options and how they compare.
The evidence behind lithium is substantial — and understanding it in the context of your own history is something a knowledgeable clinician can help with. If that kind of grounded conversation sounds useful, bipolar-specialized care is available through Sway Health with no pressure to commit to any particular path.
When weighing lithium against other approaches, it helps to explore bipolar treatment options in context — because how lithium fits into a plan often depends on whether it’s being used alone or alongside other medications. It’s also worth understanding that for many people with bipolar disorder, why antidepressants alone can worsen bipolar disorder is an important piece of the picture that lithium’s mood-stabilizing foundation directly addresses.
Lithium and Suicide Risk: What the Research Shows
This is an area where the evidence is both compelling and genuinely debated — and you deserve a clear-eyed look at both sides.
The Observational Evidence
The case for lithium’s anti-suicide effects is substantial at the observational level. A meta-analysis of observational studies found a 4.91-fold lower risk of suicides and suicide attempts in patients with recurrent major mood disorders treated with lithium — representing a 76% reduction in risk. This is not a small or fragile finding; it has appeared across multiple independent datasets and research groups over decades.
Research has specifically noted that lithium is the only drug with demonstrated efficacy in the prophylaxis of suicidal symptoms, situating this anti-suicide effect as one of its most clinically distinguishing features. Broader economic and outcomes research has also linked lithium use to reductions in overall mortality, not only from suicide.
The RCT Nuance
Here’s where intellectual honesty matters: when researchers look specifically at randomized controlled trials — the gold standard for establishing causation — the picture is less clear. A 2022 meta-analysis of RCT data found an odds ratio of 0.41 (95% CI 0.03–2.49, p = 0.45), concluding that evidence from randomized trials is inconclusive and does not support the idea that lithium prevents suicide.
The discrepancy between observational and RCT findings is likely explained by the challenges of studying suicide in trials — sample sizes, follow-up periods, and ethical constraints all limit what RCTs can detect. The honest summary is: the anti-suicide evidence for lithium is strong but not definitively proven by controlled trials. This is worth knowing as context for ongoing research, not as a reason to dismiss the medication.
Key Takeaway: The observational evidence for lithium reducing suicide risk is among the strongest in psychiatry — even as RCT data remains inconclusive due to the inherent difficulty of studying this outcome.
Lithium Side Effects: What to Expect
Side effects are one of the most common reasons people stop lithium — often before giving it a real chance, or without knowing that many effects can be managed with dose adjustments or timing changes. Knowing what’s common, what’s manageable, and what warrants a call to your prescriber gives you better footing.
Common and Often Manageable
Tremor — a fine, hand tremor — is among the most frequently reported side effects, particularly early in treatment. For many people it diminishes over time or responds well to dose timing adjustments. It’s worth flagging to your prescriber rather than stopping the medication.
Polyuria and polydipsia (increased urination and thirst) are also common, especially in early treatment. Cleveland Clinic lists these among lithium’s early side effects. Staying well-hydrated matters — dehydration can increase lithium blood levels, so consistent fluid intake is important.
Weight changes affect some people on lithium. Changes in thyroid function — which lithium can influence — sometimes contribute to weight shifts, making thyroid monitoring relevant for multiple reasons.
Cognitive effects — sometimes described as a mental “fog” or slowed processing — are reported by some people, particularly at higher doses. These effects are often dose-dependent, meaning adjustments with your prescriber’s guidance may help.
Gastrointestinal symptoms — nausea, loose stools, or stomach discomfort — are common early on and often improve after the first few weeks or with modified-release formulations. Persistent or worsening tremor, cognitive slowing that doesn’t improve, or any signs of thyroid or kidney changes should be discussed with your prescriber rather than managed silently.
Lithium Toxicity: The Narrow Therapeutic Window
The most important safety concept with lithium is its therapeutic window — the range of blood concentrations at which the medication is effective without becoming harmful. Lithium’s therapeutic window is narrow, unlike many medications that have wider margins between a helpful dose and a dangerous one.
According to StatPearls, lithium serum levels normally range from approximately 0.6 to 1.2 mEq/L (milliequivalents per liter, the unit used to measure lithium concentration in blood), and blood levels should be measured at least 6–12 hours after the last therapeutic dose. For optimal long-term efficacy, research suggests target serum levels of around 0.6–0.8 mmol/L for maintenance, with levels of 0.8–1.2 mEq/L used during acute mania treatment.
Lithium toxicity — when blood levels rise above the therapeutic range — can develop gradually or quickly, particularly during dehydration, illness, fever, sodium changes, or interactions with certain medications (particularly NSAIDs and some blood pressure medications).
Mayo Clinic describes toxicity symptoms as including diarrhea, vomiting, drowsiness, muscle weakness, tremors, and unsteadiness. Cleveland Clinic’s list includes: diarrhea, vomiting, tremors, loss of balance, uncontrollable eye movement, ringing in the ears, muscle weakness, slurred speech, and confusion.
If you experience a cluster of these symptoms — particularly in combination — contact your prescriber or seek medical attention the same day. Lithium toxicity is treatable when caught early. This isn’t meant to frighten you away from lithium; it’s meant to give you the knowledge to use it safely.
Common triggers to know about:
- Dehydration (illness, heat, exercise without adequate fluid intake)
- Sudden changes in salt/sodium intake (low-sodium diets increase lithium reabsorption)
- Starting NSAIDs like ibuprofen or naproxen
- Starting certain blood pressure medications (ACE inhibitors, thiazide diuretics)
When you know the triggers, they become manageable — not unpredictable.
Key Takeaway: Lithium toxicity is a real risk, but it’s a predictable one — understanding the triggers and recognizing early symptoms puts you in a strong position to respond quickly.
Monitoring While on Lithium
The monitoring requirements for lithium are sometimes cited as a reason to avoid it — but framed differently, they represent a structured relationship between you and a prescriber who is actively tracking your health. Here’s what that monitoring typically looks like in practice.
StatPearls monitoring guidelines specify that healthcare providers should perform kidney and thyroid function tests before initiating lithium, and that vigilant monitoring of thyroid function is imperative throughout treatment.
What Gets Monitored
Lithium blood levels: Typically checked more frequently when starting or adjusting doses (sometimes every 1–2 weeks), then less often once stable — often every 3–6 months for people on a steady, established dose.
Kidney function: Research indicates a hazard ratio of 1.93 for stage 3 chronic kidney disease with long-term lithium use — real but manageable with regular monitoring. Kidney function tests (creatinine, eGFR) are typically done at baseline, at 3–6 months, and then annually.
Thyroid function: Long-term lithium use is associated with a hazard ratio of 2.31 for hypothyroidism (underactive thyroid — when the thyroid produces too little hormone). TSH is typically checked at baseline and every 6–12 months. If hypothyroidism does develop, it’s treatable with thyroid hormone supplementation and doesn’t automatically mean stopping lithium.
Calcium levels: Research also notes a hazard ratio of 1.43 for raised serum calcium (hypercalcemia) with lithium use — another reason routine bloodwork matters. For most people on a stable lithium regimen, monitoring involves a blood draw every 3–6 months and a brief review of results with their prescriber. What it requires is a prescriber who orders the right tests, reviews results, and adjusts accordingly — that engaged prescribing relationship is itself part of lithium’s safety profile.
Sway Health’s bipolar-specialized prescribers follow structured monitoring protocols — tracking lithium levels, kidney function, and thyroid in a coordinated way, not as afterthoughts. If you’re currently on lithium without a clear monitoring schedule, or if nobody has explained what the numbers mean, that’s worth addressing. Explore bipolar treatment options and what a structured medication management relationship actually looks like.
Who Responds Best to Lithium
Given that roughly one-third of people respond excellently, one-third partially, and one-third minimally, it’s reasonable to ask: is there any way to know in advance which group you might fall into?
Clinical Predictors
Research on clinical predictors of lithium response has identified several features associated with better outcomes:
- Episode sequence: The classic pattern of mania followed by depression followed by a well interval (M-D-I) tends to predict better lithium response than other sequences.
- Absence of rapid cycling: Rapid cycling — defined as four or more mood episodes per year — has historically been associated with lower lithium response, though some research challenges this generalization.
- Absence of psychotic features: Bipolar disorder without prominent psychotic symptoms tends to be associated with better lithium response.
- Family history of bipolar disorder: A first-degree relative who responded well to lithium is associated with a higher likelihood of your own response — suggesting a genetic component.
- Fewer prior episodes: Starting lithium earlier in the course of illness is associated with better outcomes.
Notably, some research suggests lithium is equally efficacious in rapid and non-rapid cycling patients — meaning clinical predictors are guides, not guarantees in either direction.
The Precision Medicine Angle
The field is moving toward a more genetically informed understanding of lithium response. A landmark genome-wide association study (GWAS) across 2,563 patients with bipolar disorder identified variants on chromosome 21 in a long non-coding RNA gene associated with excellent lithium response — the first study large enough to detect genetic signals of this kind.
Pharmacogenomics research has begun building a precision medicine model: approximately 30% of patients are expected to be excellent responders, while up to 40% fail to respond or experience intolerable side effects. The same research notes that lithium is the most economical mood stabilizer by a factor of ten — meaning cost is rarely a barrier when access and prescribing support are in place.
This research is still developing, and genetic testing for lithium response isn’t standard clinical practice yet. But the direction of travel is toward more personalized guidance — which is a reason for cautious optimism.
Key Takeaway: Clinical and emerging genetic predictors can help inform the conversation about lithium, but individual trials with careful monitoring remain the most practical way to assess response.
Frequently Asked Questions
Can I take lithium long-term?
Yes — and for many people, that’s exactly what guidelines recommend. Lithium has been the treatment of choice for bipolar disorder for nearly 70 years and is recommended as a first-line maintenance treatment. Long-term use requires regular monitoring of kidney and thyroid function, and many people take lithium for decades without significant complications.
What happens if I stop lithium suddenly?
Abrupt discontinuation of lithium is associated with a significant risk of rapid relapse — sometimes more severe than what the person experienced before starting. This is a well-documented reason to work with a prescriber on any discontinuation rather than stopping independently, using a gradual tapering plan.
Does lithium cause permanent kidney damage?
Long-term lithium use is associated with an increased risk of stage 3 chronic kidney disease (hazard ratio 1.93) — real but modest, and manageable with regular monitoring. Catching changes in kidney function early allows for dose adjustments or hydration guidance. Many people use lithium for decades without clinically significant kidney impairment.
How is lithium different from antidepressants for bipolar disorder?
Lithium is a mood stabilizer, not an antidepressant — and this distinction matters clinically. It addresses both the elevated (manic/hypomanic) and depressive poles of bipolar disorder, providing a stabilizing foundation rather than pushing in one emotional direction. Antidepressants used without a mood stabilizer can sometimes destabilize mood in people with bipolar disorder — an important consideration when reviewing a treatment plan.
Is lithium safe during pregnancy?
Lithium and pregnancy requires careful discussion with your prescriber. The Mayo Clinic notes that lithium may affect a developing baby, and decisions about continuing, pausing, or adjusting lithium during pregnancy are highly individualized. For many people with bipolar disorder, the risk of a severe mood episode during or after pregnancy is substantial — so stopping lithium isn’t automatically the safer choice. This is a conversation worth having proactively with a bipolar-specialized prescriber, not just a general OB/GYN. Sway Health’s clinicians are experienced in navigating these intersections — reproductive planning is part of what bipolar-specialized care actually means.
Will lithium change who I am?
This is one of the most common and least-discussed concerns about lithium. Many people worry that mood stabilization means emotional flattening. At higher doses, some people do experience cognitive dulling or blunting of emotional range — worth discussing frankly with a prescriber. But many people on well-monitored lithium describe feeling more like themselves, more capable of engaging with life without the disruption of severe episodes. There’s no universal answer, which is why the ongoing prescribing relationship matters.
Conclusion: What the Evidence Invites You to Consider
Lithium’s reputation is complicated — and the evidence suggests that complication is mostly undeserved. It has over 75 years of clinical use, guideline endorsement from every major bipolar treatment body, and a unique profile: the only mood stabilizer with demonstrated prophylactic efficacy across mania, depression, and suicidal symptoms. It has real side effects and a monitoring requirement. It doesn’t work equally well for everyone. None of that makes it something to avoid — it makes it something worth understanding.
If you’re currently managing bipolar disorder, or if you’ve been told lithium might be worth considering, the conversation belongs with a clinician who knows the full evidence base and can track it properly. That kind of care is available. Finding a prescriber who understands lithium’s full evidence profile — and who can monitor it properly — makes all the difference. If your current care isn’t providing that, explore bipolar treatment through Sway Health.
